Standout Papers

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC 2021 2026 2022 2024150
  1. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC (2021)
    Michael J. Grant, Roy S. Herbst et al. Nature Reviews Clinical Oncology

Immediate Impact

23 standout
Sub-graph 1 of 11

Citing Papers

New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
Regulatory mechanisms of PD-1/PD-L1 in cancers
2024 Standout
2 intermediate papers

Works of Michael J. Grant being referenced

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
2021 Standout
Checkpoint Inhibitor use in Two Heart Transplant Patients with Metastatic Melanoma and Review of High-Risk Populations
2018

Author Peers

Author Last Decade Papers Cites
Michael J. Grant 124 167 38 45 15 265
Bamidele Adesunloye 174 175 36 42 19 328
Andrea Wahner Hendrickson 61 140 30 76 14 280
Nikolas Schopow 59 62 16 82 22 237
Daniel D. Kirchoff 96 212 71 82 22 297
Feng Liu 63 148 62 46 18 256
Aldo Lourenço Abbade Dettino 62 157 31 46 23 266
Chiyuan Amy Zhang 100 70 68 66 18 285
Valeria Stati 95 176 42 58 25 303
Delia De Lisi 123 97 47 64 18 248
Yingying Wang 60 124 69 93 13 322

All Works

Loading papers...

Rankless by CCL
2026